Last reviewed · How we verify
Gardasil 9 rescue dose
Gardasil 9 is a recombinant vaccine that stimulates the immune system to produce antibodies against nine types of human papillomavirus (HPV) to prevent infection and associated cancers.
Gardasil 9 is a recombinant vaccine that stimulates the immune system to produce antibodies against nine types of human papillomavirus (HPV) to prevent infection and associated cancers. Used for Prevention of cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58, Prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58, Prevention of genital warts caused by HPV types 6, 11.
At a glance
| Generic name | Gardasil 9 rescue dose |
|---|---|
| Also known as | Human Papillomavirus 9-valent Vaccine, Recombinant |
| Sponsor | Boston Medical Center |
| Drug class | Recombinant HPV vaccine |
| Target | Human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, 58 |
| Modality | Small molecule |
| Therapeutic area | Oncology / Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Gardasil 9 contains virus-like particles (VLPs) derived from the major capsid protein of nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58). When administered, these VLPs trigger a humoral immune response that generates neutralizing antibodies against these HPV types, preventing viral infection of epithelial cells and reducing the risk of HPV-related malignancies and genital warts. A 'rescue dose' refers to an additional dose administered to individuals who may have incomplete prior vaccination series or suboptimal immune response.
Approved indications
- Prevention of cervical cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58
- Prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, 58
- Prevention of genital warts caused by HPV types 6, 11
- Prevention of oropharyngeal and other head and neck cancers caused by HPV
Common side effects
- Injection site pain
- Injection site swelling
- Injection site erythema
- Headache
- Fever
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gardasil 9 rescue dose CI brief — competitive landscape report
- Gardasil 9 rescue dose updates RSS · CI watch RSS
- Boston Medical Center portfolio CI